Tianjin TEDA Biomedical Engineering Company Limited
Symbol: 8189.HK
HKSE
0.068
HKDMarkedspris i dag
-5.7818
P/E-forhold
0.0135
PEG Ratio
118.41M
MRK Cap
- 0.00%
DIV Udbytte
Tianjin TEDA Biomedical Engineering Company Limited (8189-HK) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 5.9 | 9.5 | 29.8 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 2.7 | 3.3 | |||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 8.8 | 31.9 | 32.1 | |||||||||||||||||||
balance-sheet.row.inventory | 0 | 90.5 | 74 | 75.2 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 85.2 | 80.3 | 75 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 190.3 | 193.1 | 208.7 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 99.7 | 118.5 | 125 | |||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 5.5 | 0 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 13.3 | 20.1 | 13.9 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 13.3 | 25.6 | 13.9 | |||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | -144.1 | -138.8 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 112.9 | 144.1 | 138.8 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 0 | 303.3 | 337.2 | 347.6 | |||||||||||||||||||
balance-sheet.row.account-payables | 0 | 16.1 | 20.7 | 29.5 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 63.3 | 60.8 | 45.1 | |||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 3.1 | 1.5 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 20.3 | 35.2 | 45.2 | |||||||||||||||||||
Deferred Revenue Non Current | 0 | -1.6 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 13.4 | 136.7 | 117.4 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 21.9 | 35.2 | 45.2 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 11.9 | 39.2 | 42.9 | |||||||||||||||||||
balance-sheet.row.total-liab | 0 | 238.7 | 253.5 | 237.2 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 3.7 | 16.8 | 16.8 | |||||||||||||||||||
balance-sheet.row.common-stock | 0 | 189.4 | 189.4 | 189.4 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -401.7 | -379 | -350.9 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -16.8 | -16.8 | -16.8 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 275.3 | 262.2 | 262.2 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 50 | 72.7 | 100.8 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 303.3 | 337.2 | 347.6 | |||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 14.6 | 11 | 9.6 | |||||||||||||||||||
balance-sheet.row.total-equity | 0 | 64.6 | 83.7 | 110.4 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||||
Total Investments | 0 | 0 | 2.7 | 3.3 | |||||||||||||||||||
balance-sheet.row.total-debt | 0 | 83.6 | 96 | 90.3 | |||||||||||||||||||
balance-sheet.row.net-debt | 0 | 77.6 | 89.2 | 63.9 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -26.5 | -44.8 | -50 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 15.4 | 9.5 | 7.1 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -1.7 | -5.3 | 43.5 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | -2.1 | 0.1 | -4.3 | ||||||||||||||||||
cash-flows.row.inventory | 0 | 1.2 | 16.4 | -2.7 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | 2.1 | -0.1 | 4.3 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -3 | -21.8 | 46.2 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 34 | 35.4 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -8.8 | -33.7 | -14 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -6.4 | 1.1 | 1.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -22.8 | -22 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0.7 | 43.8 | -1.9 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 1.5 | 3 | 10.3 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -12.9 | -8.5 | -26.5 | ||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -46.8 | -16 | -31.2 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 53 | 44.1 | 11 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 6.2 | 28.1 | -20.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -19.6 | 12.9 | -10.7 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 6.9 | 26.4 | 13.5 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 26.4 | 13.5 | 24.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -12.8 | -6.7 | 36 | ||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -8.8 | -33.7 | -14 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -21.6 | -40.4 | 22 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 398 | 449.7 | 476.4 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 376.6 | 433.3 | 430.8 | |||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 21.4 | 16.4 | 45.6 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | 0 | -0.3 | -0.1 | -0.5 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 31.2 | 38.5 | 51.8 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 407.8 | 471.8 | 482.5 | |||||||||||||||||||
income-statement-row.row.interest-income | 0 | 0.2 | 0.8 | 0.4 | |||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 5.2 | 6.4 | 5.5 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 7.3 | -5.7 | -40.4 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -0.3 | -0.1 | -0.5 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 7.3 | -5.7 | -40.4 | |||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 5.2 | 6.4 | 5.5 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 11.6 | 15.4 | 9.5 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 0 | -19.3 | -20.8 | -4.4 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -12 | -26.5 | -44.8 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | -1 | 0.2 | -0.1 | |||||||||||||||||||
income-statement-row.row.net-income | 0 | -20.2 | -26.6 | -44.8 |
Ofte stillede spørgsmål
Hvad er Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) samlede aktiver?
Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) samlede aktiver er 303277966.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er N/A.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.054.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er 0.000.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er -0.055.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er -0.045.
Hvad er Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er -20159658.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 83557328.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 31200528.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 0.000.